BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for ...
In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine ...
BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced ...
First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq. Enfortumab vedotin plus pembrolizumab in metastatic ...
The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease. A new analysis of the real-world outcomes of young ...
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC). This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This ...
ProPeer Resources, a leading independent review organization specializing in utilization management and peer review services, today announced it has earned a three-year Utilization Management (UM) ...
Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results